WO2015200161A1 - Reduction of infections in healthcare settings using photocatalytic compositions - Google Patents
Reduction of infections in healthcare settings using photocatalytic compositions Download PDFInfo
- Publication number
- WO2015200161A1 WO2015200161A1 PCT/US2015/036877 US2015036877W WO2015200161A1 WO 2015200161 A1 WO2015200161 A1 WO 2015200161A1 US 2015036877 W US2015036877 W US 2015036877W WO 2015200161 A1 WO2015200161 A1 WO 2015200161A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- infection
- healthcare
- infections
- titanium dioxide
- photocatalytic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
- A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
- A61L2/08—Radiation
- A61L2/088—Radiation using photocatalysts or photosensitisers
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/16—Disinfection, sterilisation or deodorisation of air using physical phenomena
- A61L9/18—Radiation
- A61L9/20—Ultraviolet radiation
- A61L9/205—Ultraviolet radiation using a photocatalyst or photosensitiser
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
- B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
- B01J21/063—Titanium; Oxides or hydroxides thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
- B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
- B01J21/08—Silica
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/06—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of zinc, cadmium or mercury
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
- B01J35/20—Catalysts, in general, characterised by their form or physical properties characterised by their non-solid state
- B01J35/23—Catalysts, in general, characterised by their form or physical properties characterised by their non-solid state in a colloidal state
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
- B01J35/30—Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
- B01J35/39—Photocatalytic properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
- B01J35/40—Catalysts, in general, characterised by their form or physical properties characterised by dimensions, e.g. grain size
- B01J35/45—Nanoparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/02—Processes for applying liquids or other fluent materials performed by spraying
- B05D1/04—Processes for applying liquids or other fluent materials performed by spraying involving the use of an electrostatic field
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2103/00—Materials or objects being the target of disinfection or sterilisation
- A61L2103/75—Room floors or walls
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present disclosure relates to preventing and reducing the incidence of infectious agents found on a surface and particularly on surfaces found in healthcare settings.
- infectious agents found in and on building structures and surfaces of objects therein can lead to various health problems.
- Common offending infectious agents include microorganisms such as bacteria (e.g., gram negative rods such as Escherichia coli and gram-positive cocci such as Staphylococcus aureus). These and other bacteria can cause health problems such as dermal infections, respiratory infections, intestinal infections, and kidney disease.
- pathogenic viruses such as influenza viruses are commonly found in buildings where they spread among those occupying the structure.
- infectious agents within healthcare settings lead to healthcare-associated infections which, in turn, result in greater than a billion dollars in excess healthcare costs annually. These infections have created a challenge for healthcare management teams due to multi-drug resistant bacteria becoming commonplace in healthcare settings such as hospices, hospitals, and assisted-living or long-term care facilities.
- a method of reducing the incidence of healthcare-associated infections in a healthcare facility includes the step of treating at least one inanimate surface of the healthcare facility structure, or at least one object therein, or a combination thereof, with a photocatalytic composition.
- the photocatalytic composition comprises, consists essentially of, or consists of titanium dioxide (Ti0 2 ) doped with zinc and at least one other doping agent.
- the healthcare-associated infections susceptible to treatment include bone infection, joint infection, bloodstream infection, central nervous system infection, cardiovascular system infection, pneumonia, reproductive tract infection, and surgical site infection.
- the healthcare-associated infections susceptible to treatment include gastrointestinal infection, lower respiratory infection, upper respiratory infection, skin or soft tissue infection, bloodstream infection, eye infection, ear infection, nose infection, throat infection, mouth infection, and urinary tract infection.
- the method is suitable for reducing the abundance in air and on surfaces of infectious agents including, but not limited to species of Acinetobacter, adenovirus, Bacillus, Burkholderia, Bordetella, Brucella, caliciviruses, herpes including zoster (chickenpox), Clostridium, corona viruses including SARS, MERS, and PEDV, Enterococcus, Escherichia, Hemophilus, hepatitis viruses A and B, influenza and parainfluenza viruses, Klebsiella, Listeria, Legionella, measles virus, mumps virus, Mycobacterium, Neisseria, norovirus, Pseudomonas, parvovirus, poliovirus, rhinovirus, respiratory syncytial virus, rotavirus, rubella, Salmonella, Streptococcus,
- infectious agents including, but not limited to species of Acinetobacter, adenovirus, Bacillus, Burkholderia, Bordetella
- the infectious agents that are reduced include both those susceptible to antibiotics and, without limitation, those resistant to antibiotics such as MRSA (methicillin-resistant Staphylococcus aureus, VISA (vancomycin intermediate Staphylococcus aureus), MRE (multiply resistant enterococci), and VRE (vancomycin-resistant enterococci).
- MRSA methicillin-resistant Staphylococcus aureus
- VISA vancomycin intermediate Staphylococcus aureus
- MRE multiply resistant enterococci
- VRE vancomycin-resistant enterococci
- the photocatalytic composition is applied at a rate of from about 500 ft 2 per liter to about 1800 ft 2 per liter. According to one embodiment, the
- photocatalytic composition is applied by spraying, atomizing, coating, immersion, or dipping.
- the incidence of healthcare-associated infections is reduced by at least 20% over a twelve month period after one treatment. According to another embodiment, the incidence of healthcare-associated infections is reduced by at least 30% over a twelve month period after one treatment.
- the at least one inanimate surface of the healthcare facility structure includes any or all walls, fixtures, floors, and ceilings, including those parts of hallways, offices, bathrooms, elevators, stairwells, and kitchens/cafeterias, common areas, nurses' stations, and doctors' stations.
- the at least one object of the healthcare facility includes the curtains, call buttons, computers, monitors, wall computer kiosks, blood pressure cuffs, wheelchairs, lifts, carts, and beds.
- the photocatalytic composition utilized in the methods provided herein comprises, consists essentially of, or consists of titanium dioxide that is doped with zinc and at least one other doping agent.
- the doping agent(s) increase the absorbance of light across the range of about 200 nm to about 500 nm.
- the absorbance of light of wavelengths longer than about 450 nm is less than 50% the absorbance of light of wavelengths shorter than about 350.
- the at least one other doping agent i.e., in addition to zinc
- the titanium dioxide nanoparticles have an average particle size of from about 2 nm to about 20 nm.
- the at least one other doping agent is silicon.
- the at least one other doping agent is silicon dioxide.
- the photocatalytic composition exhibits a ratio of titanium dioxide to silicon dioxide of from about 3 to about 20.
- the photocatalytic composition exhibits a ratio of titanium dioxide to zinc from about 5 to about 150 and a ratio of titanium dioxide to silicon dioxide from about 1 to about 500.
- the photocatalytic composition comprises, consists essentially of, or consists of (A) about 5000 to about 10000 ppm of titanium dioxide, (B) about 50 to about 150 ppm of zinc, and (C) about 300 to about 1000 ppm of silicon dioxide.
- a method for preventing or reducing the number of infections in a human or animal population includes the step of treating inanimate surfaces of a structure occupied by the population, or at least one inanimate object present therein, or a combination thereof, with a photocatalytic composition.
- the photocatalytic composition comprises, consists essentially of, or consists of titanium dioxide doped with zinc and at least one other doping agent.
- the structure occupied by the population includes an agricultural facility, food-processing facility, catering facility, restaurants, hotel, motel, office, or childcare facility.
- FIG. 1 is a graphic representation of solar energy capture of various Ti0 2 compositions.
- FIG. 2 is a graphic representation of the photocatalytic activity of various Ti0 2 compositions when irradiated at 354 nm.
- Methods of reducing the incidence of healthcare-associated infections in various healthcare settings are provided.
- Methods for preventing or reducing the number of infections in a human or animal population are also provided.
- the methods as provided herein reduce the abundance of various infectious agents that are commonly acquired or transmitted and are present on both animate and inanimate surfaces, including those infectious agents commonly found in healthcare settings. Further, airborne infectious agents also are reduced because such agents make contact with treated surfaces and are inactivated. By preventing and reducing the presence of such infectious agents, the incidence of various types of infection or disease is thereby reduced.
- treatment and “treating” include mitigation of a pre-existing microbial disease or infestation by application or introduction of a photocatalytic composition as provided herein to an inanimate structure or object or an animate surface.
- prevention and “prophylaxis” include reduction of the incidence or severity of disease or infestation in either individuals or populations.
- healthcare-associated infection refers to any localized or systemic condition resulting from an adverse reaction to the presence of an infectious agent (or its toxin) that was not present and without evidence of incubation at the time of admission to a healthcare setting.
- infectious agent includes, but is not limited to, viruses, mold, and bacteria that cause or contribute to infection or disease in the human population
- organisms include but are not limited to species of Acinetobacter, adenovirus, Bacillus, Burkholderia, Bordetella, Brucella, caliciviruses, herpes including zoster (chickenpox), Clostridium, corona viruses including SARS, MERS, and PEDV, Enterococcus, Escherichia, Hemophilus, hepatitis viruses A and B, influenza and parainfluenza viruses, Klebsiella, Listeria, Legionella, measles virus, mumps virus, Mycobacterium, Neisseria, norovirus, Pseudomonas, parvovirus, poliovirus, rhinovirus, respiratory syncytial virus, rotavirus, rubella, Salmonella, Streptococcus,
- the infectious agents that are reduced include both those susceptible to antibiotics and, without limitation, those resistant to antibiotics such as MRSA (methicillin-resistant Staphylococcus aureus, VISA (vancomycin intermediate Staphylococcus aureus), MRE (multiply resistant enterococci), and VRE (vancomycin-resistant enterococci).
- MRSA methicillin-resistant Staphylococcus aureus
- VISA vancomycin intermediate Staphylococcus aureus
- MRE multiply resistant enterococci
- VRE vancomycin-resistant enterococci
- the method includes the step of treating at least one inanimate surface of the healthcare facility structure, the objects (e.g., medical equipment) therein, or a combination thereof with a photocatalytic composition as provided herein.
- exemplary healthcare settings that include such structures and objects include, but are not limited to, hospitals, doctors' offices, elder or specialty care homes (e.g., assisted living, long-term care) and hospices.
- Exemplary structures of the facility subject to treatment include, but are not limited to, the walls, fixtures, floors, and ceilings, including those parts of hallways, offices, bathrooms, elevators, stairwells, and kitchens/cafeterias, common areas, nurses' stations, and doctors' stations.
- Exemplary inanimate objects in such a setting include the various equipment or medical devices that may be present including, but not limited to, curtains, call buttons, computers, monitors, wall computer kiosks, blood pressure cuffs, wheelchairs, lifts, carts, beds, and other similar objects.
- healthcare-associated infections that can be acquired or transmitted in a healthcare setting and susceptible to treatment with the photocatalytic compositions provided herein include, but are not limited to, bone and joint infection (e.g., osteomyelitis, disc space infection, joint or bursa infection, prosthetic joint infection), bloodstream infection, central nervous system infection (e.g., intracranial infection, meningitis, or ventriculitis), cardiovascular system infection (e.g., myocarditis, pericarditis, endocarditis, mediastinitis, arterial or venous infection), Eye/ear/nose/throat/mouth infection (e.g., conjunctivitis, ear infection, oral infection, sinusitis, upper respiratory infection, pharyngitis, laryngitis, epiglottitis), gastrointestinal system infection (e.g., gastroenteritis, gastrointestinal tract infection, hepatitis, intraabdominal infection, necrotizing enterocolitis), lower respiratory infection (e.g.,
- healthcare-associated infections that can be acquired or transmitted in a healthcare setting and are usceptible to treatment include gastrointestinal infection, lower respiratory infection, upper respiratory infection, skin or soft tissue infection, bloodstream infection, eye infection, ear infection, nose infection, throat infection, mouth infection, and urinary tract infection.
- the incidence of healthcare-associated infections is reduced by at least 20% over a twelve month period after one treatment as provided herein. According to a preferred embodiment, the incidence of healthcare-associated infections is reduced by at least 30% over a twelve month period after one treatment as provided herein.
- the compositions as provided herein may be applied in any known or suitable manner, including using application techniques such as spraying (e.g., electrostatic), atomizing, coating, immersion, or dipping. The best method of application may vary according to the nature of the surface to be coated.
- a preferred method is to use electrostatic spray, wherein droplets of the aqueous composition ranging in size from 5 micrometers to 100 micrometers are afforded a small electrical charge so that the droplets are attracted to the surface to be coated.
- the coating is applied as a series of two to five spraying steps with drying allowed between each step.
- the photocatalytic coating can be applied at a rate of from about 500 ft 2 per liter to about 1500 ft 2 per liter.
- a method for preventing or reducing the number of infections in a human or animal population includes treating inanimate structures used by the human or animal population, the inanimate objects that may be found within such structures, or a combination thereof, with a photocatalytic composition as provided herein.
- the step of treating the inanimate structures may include treating either a finished structure or a structure under construction.
- Exemplary settings that include such structures and objects include, but are not limited to, agricultural facilities, food-processing facilities, catering facilities, restaurants, hotels, motels, and childcare facilities.
- Exemplary parts of the structures that can be treated include, but are not limited to, walls, fixtures, floors, and ceilings, including those parts of hallways, offices, bathrooms, elevators, stairwells, and kitchens.
- the methods as provided herein utilize photocatalytic compositions that include titanium dioxide (Ti0 2 ) nanoparticles, which are useful in the prevention and reduction of infectious agents found on a surface and particularly useful in the reduction of healthcare-associated infections.
- the photocatalytic compositions as provided herein, including any nanoparticles therein, are free of any polymer or polymer composition (e.g., polymer-stabilized inorganic composition).
- the photocatalytic compositions as provided herein can be used to treat both animate and inanimate surfaces in a variety of environments where an infectious agent is located.
- the photocatalytic compositions provided herein contain only well characterized and safe materials, can be easily applied to surfaces using ordinary spray equipment, exhibit photocatalytic activity, and are effective in settings of low UV irradiance, including interior artificial lighting.
- the methods as provided herein utilize photocatalytic compositions that comprise, consist essentially of, or consist of titanium dioxide (Ti0 2 ) doped with zinc and at least one other doping agent.
- Doping agents suitable in the photocatalytic compositions provided herein, in addition to zinc include Ag, Si, C, S, Fe, Mo, Ru, Cu, Os, Re, Rh, Sn, Pt, Li, Na, and K, and combinations thereof.
- Particularly preferred doping agents include zinc and silicon.
- the composition comprises, consists essentially of, or consists of titanium dioxide doped with zinc and the ratio of titanium dioxide to zinc is from about 5 to about 150. According to a preferred embodiment, the ratio of titanium dioxide to zinc is from about 40 to about 100.
- the photocatalytic composition can further comprise, consist essentially of, or consist of silicon dioxide (Si0 2 ). According to such an embodiment, the ratio of titanium dioxide to silicon dioxide can range from about 1 to about 500. According to a preferred embodiment, the ratio of titanium dioxide to silicon dioxide is from about 3 to about 20. According to one embodiment, the titanium dioxide nanoparticles as provided herein have an average particle size of from about 2 nm to about 20 nm.
- the photocatalytic composition as provided herein comprises, consists essentially of, or consists of from about 5000 to about 10000 ppm of titanium dioxide, from about 50 to about 150 ppm of zinc, and from about 300 to about 1000 ppm of silicon dioxide.
- the photocatalytic composition as provided herein absorbs electromagnetic radiation in a wavelength range of from about 200 nm to about 500 nm.
- the absorbance of light of wavelengths longer than about 450 nm is less than 50% the absorbance of light of wavelengths shorter than about 350 nm.
- nanoscale Ti0 2 Absorption characteristics of nanoscale Ti0 2 were compared to nanoscale Ti0 2 doped with two differing zinc levels and Si0 2 , over the wavelength range of 350 nm to 500 nm.
- the nanoparticle compositions were manufactured by a modified sol-gel process, to produce formulations containing nanoparticles of anatase Ti0 2 whose average size was 6 to 7 nm.
- Zinc was incorporated as a doping agent to provide either low zinc content (0.125% relative to Ti0 2 ) or high zinc content (1.25% relative to Ti0 2 ). When Si0 2 was an additional dopant, it was present at 10% relative to Ti0 2 .
- the preparations were dried and absorbance was measured using standard methods for obtaining diffuse reflectance spectra (DRS) of powders.
- DRS diffuse reflectance spectra
- the solar irradiance (hemispherical, 37 degree tilt) from ASTM G173-03 across this spectral range is shown for reference, (See FIG. 1).
- the doped preparations absorb 25 to 35 percent more of the energy available from 400 to 450 nm, a region of the spectrum that is present in typical interior light as well as sunlight.
- Example 1 The four formulations described in Example 1 were tested for their photocatalytic activity in a standardized system. Each preparation was suspended in water at approximately 8000 ppm and applied to a glass panel using a robotic high volume low pressure sprayer, and allowed to dry for 24 hours. These panels were each attached to a glass tube to form a container, into which was placed 30 ml of an aqueous solution of methylene blue at a concentration providing an optical density of 2.3 at 664 nm. The tubes were covered with a glass panel and subjected to illumination at an energy density of approximately 0.5 mW/cm 2 from a lamp (GE item F18T8/BLB) affording ultraviolet illumination at 354 nm. This lamp provides no light at wavelengths below 300 nm or above 400 nm. The optical density of the methylene blue solution in each sample was monitored over a period of 48 hours and is shown in FIG. 2.
- FIG. 2 shows that the nanocoatings caused a decline in optical density, which results from photocatalytic degradation of the organic dye methylene blue.
- Example 1 The four formulations described in Example 1 were tested for their photocatalytic activity in a second system, in which the experimental illumination was changed to more closely mimic relevant illumination such as daylight or interior light, which are deficient in the ultraviolet energy used in Example 2. Also, for this example the nanoparticle formulations were evaluated as colloidal suspensions in 20 mM phosphate buffer, pH 7.2, rather than on a static surface. The experiment was performed in a 96-well plate format, in which each well contained methylene blue (observed OD 655 ranging from 0.05 to 0.5) and a nanoparticle formulation or appropriate controls in a final volume of 200 microliters.
- methylene blue observed OD 655 ranging from 0.05 to 0.5
- the plate was illuminated from a distance of 20 cm with light from two Sylvania Gro-Lux lamps (F20 T12 GRO/AQ). These lamps emit only 2% of their total emitted energy below 400 nm, whereas approximately 36% of their total energy is emitted between 380 and 500 nm, with a peak at 436 nm (reference: Technical Information Bulletin "Spectral Power Distributions of Sylvania Fluorescent Lamps", Osram Sylvania, www.sylvania.com).
- compositions of the four preparations tested in this experiment were independently verified by the analytical technique known as ICP-AES (inductively coupled plasma atomic emission spectrometry), which demonstrated their equivalent Ti0 2 content and variations in Si and Zn composition as described in Example 1.
- the nanoparticle preparations were diluted in buffer to provide final concentrations of 75 ppm of titanium dioxide of each formulation, with twenty replicate wells of each formulation. After a short period of equilibration in the dark, each plate was exposed to illumination with shaking, and optical density at 655 nm was measured at multiple times over using a Molecular Devices SpectraMax Plus spectrophotometer. The observed linear declines in optical density due to each formulation were measured to give the rates summarized in Table 1.
- a photocatalytic composition including titanium dioxide nanoparticles doped with zinc and silicon dioxide was prepared.
- the individual nanoparticles were approximately six to ten nanometers in dimension, and were dispersed in water to provide about 8000 ppm Ti0 2 , about 100 ppm Zn, and about 500 ppm Si0 2 .
- nanoparticles was used to coat essentially all accessible surfaces in a 42 bed health care facility that provides long term acute care services to patients after surgery and other medical procedures.
- the coating was applied using the following procedure. Vacant rooms and bathrooms were thoroughly cleaned by housekeeping staff, including removal of all linens and surface disinfection according to institutional procedures. The photocatalytic coating was then applied using electrostatic spray at a rate of about 1200 ft 2 per liter. All objects in the room were coated, including both hard and soft surface furniture and nearby walls, window and privacy curtains, and equipment such as call buttons and remote controls. Bathroom walls, fixtures, and floors were specifically coated. A minimum of 15 minutes was allowed for drying of coated surfaces, after which the room was ready for occupancy. In addition to patient rooms, all common areas, including hallways, offices, visitor restrooms, elevators, stairwells, kitchen, and nurse's stations (including computers) were coated. Equipment was also coated, including wall computer kiosks, blood pressure cuffs, wheelchairs, lifts, carts, and other similar surfaces.
- the healthcare facility made no changes to institutional infection control processes or procedures.
- the number of infections were recorded in compliance with existing institutional protocols.
- Table 2 reports the number of infections occurring in each quarter of the year following treatment, compared with the number of infections at the same institution during the same quarter of the year prior to treatment. Infections were fewer in every quarter after treatment than in any quarter prior to treatment. When summed over the entire assessment period, infections declined 40% in the year following surface coating with the photocatalytic composition.
- Example 4 The composition described in Example 4 was applied using the procedure described in Example 4 to a 250 bed health care facility that provides sub-acute long term residential care. Similar to Example 4, no change was made to institutional processes or procedures, and infections occurring in the facility were enumerated in accord with standard protocols. Table 3 reports the number of infections occurring in each quarter of the year following treatment, compared with the number of infections at the same institution during the same quarter of the year prior to treatment. Infections were fewer in every quarter after treatment compared to any quarter prior to treatment. When summed over the entire assessment period, infections declined 32 % in the year following surface coating with the photocatalytic composition.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Catalysts (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020177001585A KR102493213B1 (ko) | 2014-06-23 | 2015-06-22 | 광촉매 조성물을 이용한 건강관리 시설에서 건강관리-관련 감염의 발생을 감소시키는 방법 |
| EP15811053.6A EP3160233A4 (en) | 2014-06-23 | 2015-06-22 | Reduction of infections in healthcare settings using photocatalytic compositions |
| CA2953515A CA2953515C (en) | 2014-06-23 | 2015-06-22 | Reduction of infections in healthcare settings using photocatalytic compositions |
| JP2017521067A JP6749320B2 (ja) | 2014-06-23 | 2015-06-22 | 光触媒組成物を用いた医療現場での感染の低減 |
| AU2015280348A AU2015280348B2 (en) | 2014-06-23 | 2015-06-22 | Reduction of infections in healthcare settings using photocatalytic compositions |
| NZ728027A NZ728027B2 (en) | 2015-06-22 | Reduction of infections in healthcare settings using photocatalytic compositions | |
| CN201580033827.5A CN106535639A (zh) | 2014-06-23 | 2015-06-22 | 使用光催化组合物在医疗保健装置中减少感染 |
| MX2016016865A MX381870B (es) | 2014-06-23 | 2015-06-22 | Reduccion de infecciones en instalaciones de atencion medica usando composiciones fotocataliticas. |
| IL249488A IL249488B (en) | 2014-06-23 | 2016-12-11 | Reduction of infections in healthcare settings using photocatalytic compositions |
| ZA2017/00244A ZA201700244B (en) | 2014-06-23 | 2017-01-11 | Reduction of infections in healthcare settings using photocatalytic compositions |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015596P | 2014-06-23 | 2014-06-23 | |
| US62/015,596 | 2014-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015200161A1 true WO2015200161A1 (en) | 2015-12-30 |
Family
ID=54868693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2015/036877 Ceased WO2015200161A1 (en) | 2014-06-23 | 2015-06-22 | Reduction of infections in healthcare settings using photocatalytic compositions |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150367007A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3160233A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6749320B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102493213B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106535639A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015280348B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2953515C (cg-RX-API-DMAC7.html) |
| IL (1) | IL249488B (cg-RX-API-DMAC7.html) |
| MX (1) | MX381870B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015200161A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201700244B (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11819580B2 (en) | 2016-10-18 | 2023-11-21 | PurWorld Technologies LLC | Method of chemically disinfecting a vehicle |
| CN111107747A (zh) * | 2018-08-29 | 2020-05-05 | 株式会社日吉 | 对于军团菌属菌的消毒剂、水处理方法、浴槽水用添加剂和空调冷却塔水用添加剂 |
| US20210353806A1 (en) * | 2020-05-14 | 2021-11-18 | Healthe, Inc. | Elevator sterilization system and associated methods |
| WO2022040379A1 (en) * | 2020-08-20 | 2022-02-24 | Current Lighting Solutions, Llc | System and method to disinfect a room using ultraviolet light and a photocatalyst |
| KR102208783B1 (ko) * | 2020-10-08 | 2021-01-28 | 애드문코퍼레이션 주식회사 | 분무 조성물 및 이의 제조방법 |
| CN117425503A (zh) * | 2021-01-08 | 2024-01-19 | 希内克西斯有限责任公司 | 医疗卫生机构高接触表面的微生物控制 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006240995A (ja) * | 2005-02-28 | 2006-09-14 | Central Res Inst Of Electric Power Ind | 医家向け抗菌製品およびその取り扱い方法 |
| US20090054238A1 (en) * | 2005-07-28 | 2009-02-26 | Evonik Degussa Gmbh | Preparation containing a photocatalytically active metal oxide powder and a wetting agent |
| US20090110918A1 (en) * | 2005-04-11 | 2009-04-30 | Saint-Gobain Glass France | Microbicidal Substrate |
| US20140099348A1 (en) * | 2011-05-04 | 2014-04-10 | Stewart Benson Averett | Titanium Dioxide Photocatalytic Compositions and Uses Thereof |
| EP2597950B1 (en) * | 2011-10-12 | 2014-04-16 | Showa Denko K.K. | Antimicrobial and antiviral composition comprising cuprous oxide, and method of producing the same |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0076158B1 (en) | 1981-09-30 | 1989-10-25 | National Research Development Corporation | Compositions comprising encapsulated particles |
| US6387844B1 (en) | 1994-10-31 | 2002-05-14 | Akira Fujishima | Titanium dioxide photocatalyst |
| FR2776944B1 (fr) | 1998-04-03 | 2000-05-12 | Ahlstrom Paper Group Research | Composition photocatalytique |
| KR20000009824A (ko) | 1998-07-29 | 2000-02-15 | 여광웅 | 동식물성 유기폐기물의 멸균장치 |
| JP3458948B2 (ja) | 1999-07-01 | 2003-10-20 | 博 河合 | 植物茎葉散布用組成物およびその使用方法 |
| KR100357765B1 (ko) | 1999-11-25 | 2002-10-25 | (주)바이오세라 | 광반도성 탈취/항균 필터의 제조 방법 및 이에 의해 제조된 광반도성 탈취/항균필터 |
| IL133364A0 (en) | 1999-12-07 | 2001-04-30 | Progeny Biolog Systems | A method and system for treatment of animal waste |
| JP2001286226A (ja) | 2000-04-06 | 2001-10-16 | Tsunetaka Yokoyama | 農業用ビニールハウスの天井等に酸化チタン及びセラミックス粉末を接着させる方法 |
| JP2001314882A (ja) | 2000-05-09 | 2001-11-13 | Dreams:Kk | バイオ浄化資材およびその製造方法 |
| US20020187082A1 (en) | 2001-06-06 | 2002-12-12 | Chang-Yu Wu | Photocatalyst coated magnetic composite particle |
| AU2003202894A1 (en) * | 2002-01-07 | 2003-07-24 | Jack W. Long | Topical treatment for carpet and textiles and topically treated carpet and textile products |
| EP1468737A4 (en) | 2002-01-21 | 2005-09-21 | Sumitomo Titanium Corp | PHOTOCATALYTIC COMPOSITE MATERIAL AND PROCESS FOR PREPARING THE SAME |
| JP4308674B2 (ja) | 2002-04-16 | 2009-08-05 | 株式会社ルネサステクノロジ | 半導体装置の製造方法 |
| HK1050811A2 (en) | 2002-05-09 | 2003-06-13 | 爱环保有限公司 | A fluid purification and disinfection device |
| US7449245B2 (en) | 2002-07-09 | 2008-11-11 | Leibniz-Institut Fuer Neue Materialien Gemeinnuetzige Gmbh | Substrates comprising a photocatalytic TiO2 layer |
| US20040060677A1 (en) | 2002-09-27 | 2004-04-01 | Ching-Chung Huang | Multi-functional paper and a method making the same |
| WO2004037301A2 (en) | 2002-10-24 | 2004-05-06 | Georgia Tech Research Corporation | Systems and methods for disinfection |
| EP1633818A2 (en) | 2003-04-18 | 2006-03-15 | MERCK PATENT GmbH | Antimicrobial pigments |
| JP2005040769A (ja) | 2003-07-25 | 2005-02-17 | Yukio Hirose | 水質改善構造体およびこれを用いた水質改善方法 |
| EP1709123A2 (en) | 2004-01-28 | 2006-10-11 | Oxonica Limited | Surface-doped particles of tio2 or zno and their use |
| JP2006321721A (ja) | 2005-05-17 | 2006-11-30 | Shinto Paint Co Ltd | 開花、結実促進剤 |
| ITMI20051558A1 (it) | 2005-08-09 | 2007-02-10 | Isagro Spa | Miscele e-o composizioni sinergiche cin elevata attivita'fungicida |
| ITIS20050002A1 (it) | 2005-09-01 | 2007-03-02 | Jokero Inv Srl | Filtri fotocatalitici ricoperti con sospensioni di biossido di titanio ed altri composti e metodi per otteneri detti filtri. |
| FR2900351B1 (fr) | 2006-04-26 | 2008-06-13 | Commissariat Energie Atomique | Procede de preparation d'une couche nanoporeuse de nanoparticules et couche ainsi obtenue |
| CN100395020C (zh) * | 2006-07-21 | 2008-06-18 | 浙江大学 | 锌和硅共掺杂的纳米二氧化钛光催化剂及其制备方法和应用 |
| ES2487665T3 (es) | 2006-10-12 | 2014-08-22 | Nm Tech Nanomaterials Microdevice Technology, Ltd. | Uso de una composición con propiedades antimicrobianas |
| CN101588722A (zh) | 2007-01-23 | 2009-11-25 | 默克专利股份有限公司 | 包含氧化锌、硫酸钡和银离子的抗微生物组合物 |
| WO2008093398A1 (ja) | 2007-01-30 | 2008-08-07 | Asics Corporation | シューズの製造方法、及びシューズ |
| US20080187457A1 (en) * | 2007-02-05 | 2008-08-07 | Mangiardi John R | Antibacterial Titanium Dioxide Compositions |
| WO2008135093A1 (en) | 2007-05-08 | 2008-11-13 | Nm Tech Nanomaterials Microdevice Technology Ltd. | Products comprising an anti-microbial composition based on titanium dioxide nanoparticles |
| WO2009030641A1 (en) | 2007-09-06 | 2009-03-12 | Vitec Speciality Chemicals Limited | Water-stabilized antimicrobial organosilane compositions, and methods for using the same |
| US20090068089A1 (en) | 2007-09-08 | 2009-03-12 | Quaid-E-Azam University | Novel method of manufacture of silver oxide nano particles |
| JP2009084542A (ja) | 2007-10-02 | 2009-04-23 | Sun Medic Corp | 抗菌性水性組成物 |
| WO2009051817A1 (en) | 2007-10-19 | 2009-04-23 | One Green World, Inc. | Photocatalytic titanium dioxide nanocrystals |
| US20090169425A1 (en) | 2007-12-27 | 2009-07-02 | Industry-Academic Cooperation Foundation, Yonsei University | Apparatus and method for disinfecting food using photo-catalytic reaction of titanium dioxide and ultraviolet rays |
| GB2472968B (en) | 2008-07-08 | 2012-11-07 | Andrew Tye Hunt | Antimicrobial coatings |
| EA201101426A1 (ru) | 2009-04-02 | 2012-05-30 | Басф Се | Способ подавления вредных грибов |
| US20110124492A1 (en) | 2009-09-17 | 2011-05-26 | Nikolai Loukine | Multifunctional Nanocomposites |
| CN101905166B (zh) | 2010-07-27 | 2012-07-25 | 中国地质大学(武汉) | 一种可磁分离的氮掺杂TiO2光催化剂及其制备方法 |
| US9987621B2 (en) * | 2012-01-12 | 2018-06-05 | Nitto Denko Corporation | Transparent photocatalyst coating |
-
2015
- 2015-06-22 WO PCT/US2015/036877 patent/WO2015200161A1/en not_active Ceased
- 2015-06-22 CN CN201580033827.5A patent/CN106535639A/zh active Pending
- 2015-06-22 MX MX2016016865A patent/MX381870B/es unknown
- 2015-06-22 JP JP2017521067A patent/JP6749320B2/ja active Active
- 2015-06-22 KR KR1020177001585A patent/KR102493213B1/ko active Active
- 2015-06-22 EP EP15811053.6A patent/EP3160233A4/en not_active Withdrawn
- 2015-06-22 CA CA2953515A patent/CA2953515C/en active Active
- 2015-06-22 AU AU2015280348A patent/AU2015280348B2/en active Active
- 2015-06-22 US US14/745,592 patent/US20150367007A1/en not_active Abandoned
-
2016
- 2016-09-13 US US15/263,925 patent/US10434203B2/en active Active
- 2016-12-11 IL IL249488A patent/IL249488B/en active IP Right Grant
-
2017
- 2017-01-11 ZA ZA2017/00244A patent/ZA201700244B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006240995A (ja) * | 2005-02-28 | 2006-09-14 | Central Res Inst Of Electric Power Ind | 医家向け抗菌製品およびその取り扱い方法 |
| US20090110918A1 (en) * | 2005-04-11 | 2009-04-30 | Saint-Gobain Glass France | Microbicidal Substrate |
| US20090054238A1 (en) * | 2005-07-28 | 2009-02-26 | Evonik Degussa Gmbh | Preparation containing a photocatalytically active metal oxide powder and a wetting agent |
| US20140099348A1 (en) * | 2011-05-04 | 2014-04-10 | Stewart Benson Averett | Titanium Dioxide Photocatalytic Compositions and Uses Thereof |
| EP2597950B1 (en) * | 2011-10-12 | 2014-04-16 | Showa Denko K.K. | Antimicrobial and antiviral composition comprising cuprous oxide, and method of producing the same |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP3160233A4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015280348A1 (en) | 2017-02-02 |
| US20160375164A1 (en) | 2016-12-29 |
| EP3160233A4 (en) | 2018-03-07 |
| JP2017523892A (ja) | 2017-08-24 |
| KR20170048318A (ko) | 2017-05-08 |
| NZ728027A (en) | 2023-12-22 |
| US10434203B2 (en) | 2019-10-08 |
| CA2953515A1 (en) | 2015-12-30 |
| MX2016016865A (es) | 2017-07-27 |
| US20150367007A1 (en) | 2015-12-24 |
| JP6749320B2 (ja) | 2020-09-02 |
| KR102493213B1 (ko) | 2023-01-27 |
| ZA201700244B (en) | 2022-05-25 |
| MX381870B (es) | 2025-03-13 |
| CA2953515C (en) | 2023-04-25 |
| IL249488A0 (en) | 2017-02-28 |
| EP3160233A1 (en) | 2017-05-03 |
| CN106535639A (zh) | 2017-03-22 |
| IL249488B (en) | 2020-07-30 |
| AU2015280348B2 (en) | 2019-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10434203B2 (en) | Reduction of infections in healthcare settings using photocatalytic compositions | |
| Emmanuel et al. | Architectural design strategies for infection prevention and control (IPC) in health-care facilities: towards curbing the spread of Covid-19 | |
| US20090104086A1 (en) | Photocatalytic titanium dioxide nanocrystals | |
| Weber et al. | Continuous room decontamination technologies | |
| Bolookat et al. | Assessment of bioaerosol particle characteristics at different hospital wards and operating theaters: a case study in Tehran | |
| US9724440B2 (en) | Environmental cleaning and antimicrobial lighting component and fixture | |
| BR122019017167B1 (pt) | Composições fotocatalíticas e método para tratar ou prevenir infestações sobre superfície | |
| Salonen et al. | Methods for infection prevention in the built environment—a mini-review | |
| De Jong et al. | Pre–post evaluation of effects of a titanium dioxide coating on environmental contamination of an intensive care unit: the TITANIC study | |
| JP2017523892A5 (cg-RX-API-DMAC7.html) | ||
| Taneja et al. | Hydrogen peroxide vapour for decontaminating air-conditioning ducts and rooms of an emergency complex in northern India: time to move on | |
| Hakim et al. | Effect of a shielded continuous ultraviolet-C air disinfection device on reduction of air and surface microbial contamination in a pediatric oncology outpatient care unit | |
| Narouei et al. | Effects of germicidal far-UVC on ozone and particulate matter in a conference room | |
| Tallosy et al. | LED-light activated antibacterial surfaces using silver-modified TiO2 embedded in polymer matrix | |
| RU169520U1 (ru) | Очиститель и обеззараживатель воздуха | |
| Kallawicha et al. | Modern solutions for indoor air quality management in commercial and residential spaces | |
| US20230248866A1 (en) | Portable hydroxyl ion generator apparatus | |
| Ramsden | Photocatalytic antimicrobial coatings | |
| US11013822B1 (en) | Smallest particulate absorber | |
| Senneby et al. | Decontamination of patient bathroom surfaces with 405 nm violet-blue light irradiation in a real-life setting | |
| EP4185340A1 (en) | Nanoparticles, nanofunctionalised substrate and device with antiviral and/or antibacterial and/or antifungal photocatalytic activity | |
| Maclean | An investigation into the light inactivation of medically important microorganisms | |
| IT202000018004A1 (it) | Nanoparticelle, substrato nanofunzionalizzato e dispositivo con attività fotocatalitica antibatterica | |
| Decraene et al. | Enhancement by nanogold of the efficacy of a light-activated antimicrobial coating | |
| Dunnill et al. | Antimicrobial coatings for ‘self-sterilisation’ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15811053 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 249488 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/016865 Country of ref document: MX |
|
| ENP | Entry into the national phase |
Ref document number: 2017521067 Country of ref document: JP Kind code of ref document: A Ref document number: 2953515 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 20177001585 Country of ref document: KR Kind code of ref document: A |
|
| REEP | Request for entry into the european phase |
Ref document number: 2015811053 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2015811053 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2015280348 Country of ref document: AU Date of ref document: 20150622 Kind code of ref document: A |